Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 21

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 21
---
arepta Collaboration, $325.0 million in the form of an equity investment under the Stock Purchase Agreement, and $250.0 million to be paid in annual installments of $50.0 million over 5 years. The Company is also eligible to receive $300.0 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study, which the Company is on track to achieve. Further, for each of the 13 programs, the Company is eligible to receive development milestone payments between $110.0 million and $180.0 million per program and sales milestone payments between $500.0 million and $700.0 million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits. Platform In fiscal 2024, the Company continued to develop and deploy its Targeted RNAi Molecule platform (“ TRiM ™ ”) to identify and develop new therapeutics. TRiM ™ utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting, while being structurally simple. Targeting has been core to the Company’s development philosophy and the TRiM TM platform builds on more than a decade of work on actively targeted drug delivery vehicles. The TRiM ™ platform is designed to offer several potential competitive advantages including: • A more sophisticated RNAi trigger selection and screening process that identifies potent sequences rapidly in locations that RNAi competitors may miss; • Multiple routes of administration including subcutaneous, intravenous and inhaled; • Faster time to clinical candidates; • Optimal pharmacologic activity and long duration-of-effect; • Potentially wide safety margins; • Simplified manufacturing at reduced cost; and • The ability to take RNAi to tissues beyond the liver.

| 24 |

2025 PROXY STATEMENT Executive Compensation Pipeline Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of Arrowhead's RNAi technologies enables Arrowhead to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is focused on bringing the promise of RNAi to address diseases outside of the liver, and its pipeline now includes disease targets in the liver, lung, muscle and CNS. The timing of our planned and already filed clinical trial applications (“ CTA ”) discussed below are based on calendar years,